METTL17 and leukemia: Although METTL17 did not itself impact growth in K562 cells, it was nonetheless identified in our ATP screen performed in K562 human leukemia cells; these subsequent studies link METTL17 to a cancer-relevant endpoint in a different cancer cell line—in this case, human lung cancer cells—in which stable silencing of METTL17 significantly suppresses basal cancer cell proliferation without producing increased apoptosis.